Kellerhals Carrard with MoonLake on debt funding by Hercules Capital
Kellerhals Carrard advised Swiss clinical-stage biotechnology company MoonLake Immunotherapeutics on its agreement with American venture lending specialist Hercules Capital for up to $500 million in non-dilutive capital, with an initial $75 million drawn at closing.
Pursuant to the deal, additional tranches will become available upon achievement of certain pre-specified milestones in alignment with MoonLake’s strategy and funding needs.
The company
Headquartered in Zug, MoonLake Immunotherapeutics utilizes its Nanobody technology to develop medicines for immunologic diseases, including inflammatory skin and joint diseases.
The Kellerhals Carrard team
Partner Nicolas Mosimann (pictured) led the Kellerhals Carrard startup & VC desk team on the matter, working alongside partner Marco Sibold (tax/corporate). Senior associate Kevin MacCabe, as well as associates Jon Oetiker and Kim Lindner, further contributed to the effort.
